Tech Company Financing Transactions
CureVac Funding Round
Baillie Gifford, Bill & Melinda Gates Foundation and Chartwave Limited participated in a $110 million funding round for CureVac. The financing round closed on 11/4/2015.
Transaction Overview
Company Name
Announced On
11/4/2015
Transaction Type
Venture Equity
Amount
$110,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The funding comes as CureVac pursues a Phase IIb study for its lead therapeutic cancer vaccine program and sets its sights on adding a new industrial-scale manufacturing facility that can provide the product needed to get its therapies through the clinic.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
15 Paul-Ehrlich-Strasse
Tübingen, 72076
Germany
Tübingen, 72076
Germany
Phone
Website
Email Address
Overview
CureVac (Nasdaq: CVAC) is a biopharmaceutical company specializing in the prophylactic and therapeutic application of messenger RNA.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Daniel Menichella
Chief Financial Officer
Pierre Kemula
Chief Operating Officer
Franz-Werner Haas
Chief Scientific Officer
Mariola Fotin-Mleczek
Founder
Ingmar Hoerr
VP - Product Management
Florian Mülbe
Browse more venture capital transactions:
Prev: 11/4/2015: Specialists on Call venture capital transaction
Next: 11/4/2015: FactorTrust venture capital transaction
Share this article
About Database of VC Transactions
We report on tech company VC transactions. All VC database entries reported here are derived from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs